The buy is a “significant milestone” for Vanda, CEO and chairman Mihael H. Polymeropoulos, M.D., said in a statement. The deal "expands our commercial portfolio and gives us access to a versatile immune response modifier that can potentially have broad application in treating a number of autoimmune-based disorders," the chief added.
J&J's sale of certain Ponvory rights comes after Fierce Pharma in February reported that the pharma company had laid off some members of its multiple sclerosis sales team. The drugmaker has yet to reveal sales figures for Ponvory.
On the horizon for Vanda is gastroparesis med tradipitant, which, if approved, would be the first novel drug for the condition in over four decades. The FDA accepted the company's approval application earlier this month and set a decision date for next September.
Hetlioz and Fanapt are also due for FDA decisions on potential label expansions next year.
Meanwhile, Vanda has spent the last few years quarreling with the FDA over its 2019 rejection of Hetlioz in jet lag disorder. Earlier this year, a Washington D.C. district court sided with Vanda and ordered the FDA to release relevant records.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.